-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since last year, the pace of promotion of centralized procurement of proprietary Chinese medicines has been accelerating, and the scope has also been expanding
.
This can be clearly seen from the centralized procurement of Chinese patent medicines in Hubei Alliance and Guangdong Alliance that have been completed before
.
Specifically, the centralized procurement of Chinese patent medicines in the 19-province alliance in Hubei will officially "end" at the end of 2021, and it has now entered the stage of distributing the procurement volume
.
This centralized procurement involved 76 major varieties, with a procurement scale of nearly 10 billion yuan.
In the end, 97 companies and 111 products were selected, with a selection rate of 62%, an average decrease of 42.
27%, and a decrease of 82.
63%
.
In addition, the centralized procurement of Chinese patent medicines of the 6-province alliance in Guangdong also announced the results of the proposed selection/alternative recently.
The centralized procurement involved 53 major varieties.
In the end, 361 products from 174 companies were proposed to be selected/alternative.
Among them, the exclusive varieties proposed to win the bid on average.
The decline is around 20%, and the average decline in bids for non-exclusive varieties is 67.
8%
.
As the centralized procurement of Hubei Alliance and Guangdong Alliance covering more than half of China has settled, industry analysts believe that, on the whole, the special centralized procurement of proprietary Chinese medicines has officially entered the substantive start-up stage from the level of discussion and preparation
.
In the future, the centralized procurement of Chinese patent medicines with volume will still take "price for volume" as the core guiding principle, and focus on purchasing varieties with large clinical needs to meet the needs of patients
.
Under the normalization and institutionalization of centralized procurement, industry insiders suggest that the transformation and upgrading of Chinese patent medicine enterprises need to be further accelerated
.
In fact, under the promotion of a series of TCM policies, TCM pharmaceutical companies have begun to accelerate their transformation and upgrading
.
In terms of innovation, enthusiasm is running high.
According to the data of the Center for Drug Evaluation of the State Drug Administration, 27 new Chinese medicines will be approved for approval in 2020, 62 new Chinese medicines will be approved in 2021, and 18 new Chinese medicines will be approved by the end of March in 2022.
.
In addition, it is worth mentioning that many companies are currently increasing investment in research and development to accelerate the innovation of traditional Chinese medicine
.
For example, Guangzhou Baiyunshan has been continuously promoting the layout of innovative drugs in recent years, and has increased investment in research and development year by year
.
The financial report shows that in 2021, the research and development expenses of Guangzhou Baiyunshan will be 875 million yuan, a year-on-year increase of 42.
94%.
.
In general, the innovative research and development of traditional Chinese medicine is obviously improving in quality and growth
.
Under the background that the development of the traditional Chinese medicine industry has obviously become a long-term plan of the country and even all regions, the industry believes that due to favorable policies and the pressure of centralized procurement, pharmaceutical companies will start to strengthen the research and development of traditional Chinese medicine products in order to further expand their performance.
At the same time, more and more new Chinese medicines will emerge in the industry one after another
.
However, it should be noted that in the face of the normalization of centralized procurement and the cost test of Chinese patent medicines, how to strengthen the bargaining power over the upstream industry chain, and even extend its own business to the upstream industry chain, self-built production bases for Chinese medicinal materials, or will become a Chinese herbal medicine production base.
The problems that need to be solved urgently to enhance the competitiveness of patent medicine enterprises
.
In addition, innovative research and development of proprietary Chinese medicines, improving cost advantages and even expanding overseas markets will increasingly become an important direction for enterprises to transform and upgrade
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
This can be clearly seen from the centralized procurement of Chinese patent medicines in Hubei Alliance and Guangdong Alliance that have been completed before
.
Specifically, the centralized procurement of Chinese patent medicines in the 19-province alliance in Hubei will officially "end" at the end of 2021, and it has now entered the stage of distributing the procurement volume
.
This centralized procurement involved 76 major varieties, with a procurement scale of nearly 10 billion yuan.
In the end, 97 companies and 111 products were selected, with a selection rate of 62%, an average decrease of 42.
27%, and a decrease of 82.
63%
.
In addition, the centralized procurement of Chinese patent medicines of the 6-province alliance in Guangdong also announced the results of the proposed selection/alternative recently.
The centralized procurement involved 53 major varieties.
In the end, 361 products from 174 companies were proposed to be selected/alternative.
Among them, the exclusive varieties proposed to win the bid on average.
The decline is around 20%, and the average decline in bids for non-exclusive varieties is 67.
8%
.
As the centralized procurement of Hubei Alliance and Guangdong Alliance covering more than half of China has settled, industry analysts believe that, on the whole, the special centralized procurement of proprietary Chinese medicines has officially entered the substantive start-up stage from the level of discussion and preparation
.
In the future, the centralized procurement of Chinese patent medicines with volume will still take "price for volume" as the core guiding principle, and focus on purchasing varieties with large clinical needs to meet the needs of patients
.
Under the normalization and institutionalization of centralized procurement, industry insiders suggest that the transformation and upgrading of Chinese patent medicine enterprises need to be further accelerated
.
In fact, under the promotion of a series of TCM policies, TCM pharmaceutical companies have begun to accelerate their transformation and upgrading
.
In terms of innovation, enthusiasm is running high.
According to the data of the Center for Drug Evaluation of the State Drug Administration, 27 new Chinese medicines will be approved for approval in 2020, 62 new Chinese medicines will be approved in 2021, and 18 new Chinese medicines will be approved by the end of March in 2022.
.
In addition, it is worth mentioning that many companies are currently increasing investment in research and development to accelerate the innovation of traditional Chinese medicine
.
For example, Guangzhou Baiyunshan has been continuously promoting the layout of innovative drugs in recent years, and has increased investment in research and development year by year
.
The financial report shows that in 2021, the research and development expenses of Guangzhou Baiyunshan will be 875 million yuan, a year-on-year increase of 42.
94%.
.
In general, the innovative research and development of traditional Chinese medicine is obviously improving in quality and growth
.
Under the background that the development of the traditional Chinese medicine industry has obviously become a long-term plan of the country and even all regions, the industry believes that due to favorable policies and the pressure of centralized procurement, pharmaceutical companies will start to strengthen the research and development of traditional Chinese medicine products in order to further expand their performance.
At the same time, more and more new Chinese medicines will emerge in the industry one after another
.
However, it should be noted that in the face of the normalization of centralized procurement and the cost test of Chinese patent medicines, how to strengthen the bargaining power over the upstream industry chain, and even extend its own business to the upstream industry chain, self-built production bases for Chinese medicinal materials, or will become a Chinese herbal medicine production base.
The problems that need to be solved urgently to enhance the competitiveness of patent medicine enterprises
.
In addition, innovative research and development of proprietary Chinese medicines, improving cost advantages and even expanding overseas markets will increasingly become an important direction for enterprises to transform and upgrade
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
